Targeting LncRNAs in Cardiovascular Disease: Options and Expeditions.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28209793.
- Also identified by DOI 10.1161/CIRCRESAHA.116.310152 and PMC identifier 5325063.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nucleic acid-based therapeutics constitutes the next frontier in cardiovascular disease (CVD) management. Recent findings have shown a strong regulatory role of a new class of non-coding RNAs (ncRNAs) known as long ncRNAs (lncRNAs), on biological pathways, cell function, and cardiovascular tissue homeostasis in health and disease. Accumulating studies demonstrate that lncRNAs may regulate protein-coding genes, RNAs, and epigenetic factors in a tight spatial and temporal manner. Herein, we discuss key technical hurdles, current limitations and challenges as well as advantages and disadvantages of emerging experimental methods in the lncRNA field.
Medical subject headings
- Cardiovascular Diseases
- Gene Editing
- Molecular Targeted Therapy
- RNA, Long Noncoding